October 2, 2025Circulation Heart Failure
Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock
Key result
Higher plasma VEGFR1 levels are linked to ~6% higher 180-day mortality in AMI cardiogenic shock.
- HR 1.06
- 95% CI 1.03-1.09
- P<0.001
- n=488
Why the study?
Are elevated plasma VEGFR1 levels associated with increased 180-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock?
Population
488 patients across three cohorts: an exploration cohort, a validation cohort, and a third cohort.
Comparison
Measurement of plasma VEGFR1 levels vs AMI without shock and lower VEGFR1 levels
Design
Cohort
Follow-up
180 days
Authors
Discussion
Loading...
Member takes
Implication
Elevated plasma VEGFR1 levels serve as an early, independent prognostic biomarker for 180-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.
Key Points
- Elevated VEGFR1 levels in patients with cardiogenic shock predict higher mortality risk after 180 days.
- In independent validation, nonsurvivors had significantly higher VEGFR1 levels compared to survivors.
- Cox regression analysis showed VEGFR1 as an independent predictor of 180-day mortality risk, beyond standard clinical indicators.
- Continuous monitoring of VEGFR1 levels in patients illustrates its potential as an early prognostic biomarker.
Study Design
Type
Cohort (n=488)
Structured PICO
Are elevated plasma VEGFR1 levels associated with increased 180-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock?
P
Population
488 patients with acute myocardial infarction (479 with cardiogenic shock) across exploration, validation, and temporal cohorts, evaluated for 180-day survival.
E
Exposure
Measurement of plasma VEGFR1 (vascular endothelial growth factor receptor 1) levels
C
Comparator
AMI without shock (in exploration cohort) and lower VEGFR1 levels (in validation cohort)
O
Outcome
180-day survivalhard clinical
Main Result
Hazard Ratio: 1.06 (95% CI 1.03–1.09)
p-value: p=<0.001
Elevated plasma VEGFR1 levels serve as an early, independent prognostic biomarker for 180-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.
Cite This Study
Jung et al. (2025) conducted a cohort in Acute myocardial infarction with cardiogenic shock (n=488). Plasma VEGFR1 levels was evaluated on 180-day survival (HR 1.06, 95% CI 1.03-1.09, p=<0.001). Higher plasma VEGFR1 levels were independently associated with an increased 180-day mortality risk in patients with acute myocardial infarction and cardiogenic shock (HR 1.06; 95% CI 1.03-1.09; P<0.001).